to consOgy alone is difficult, but shows the need to consider AZD8931 to take m Possible differences in clinical trials. Additionally Tzlich, unlike HCV, HBV reactive immunosuppression, which complicates the treatment with immunosuppressive therapy. The prevalence Pr HBV in Asia, HCC is increased with a FITTINGS use of antiviral agents for Pr Prevention of viral reactivation w During treatment associated HCC. Antiviral therapy with lamivudine has the incidence of HBV reactivation and hepatitis reduces the severity of the consequences of hepatitis, led to fewer interruptions in chemotherapy and reduction of mortality t with reactivation associated HBV in clinical trials in patients with HCC or other cancers, that re oivent chemotherapy.
Antiviral therapy after curative resection, radiofrequency ablation, or other local chemotherapy for HBV, HCC has been shown to increase the volume of the remaining liver function erh hen And can survive or leased Ngern. In addition, interferon has given after curative treatment, the survival rate increased to hen without relapse. These advantages show that the use of antiviral Tandutinib therapy is an important factor of confusion in clinical HCC. An international jury has recommended separate stratification by region for global studies, but not recommended stratified by Etiology. But given the St Rfaktoren described here, the jury recommended that the current studies in East Asia should be stratified by HBV or HCV Contain etiology. Moreover, antiviral therapy be considered both as a stratification factor and integrated into the overall management of patients in international clinical trials HCC.
Screening at diagnosis differs both in East Asia and between East Asia and Western countries L. With the TNM system basis, China and Japan have relatively high proportion of patients diagnosed with stage I or II, compared to Hong Kong and Korea. In the United States an h Herer percentage of patients with distant metastases compared to Asian L Diagnosed change. The differences k Can reflect screening process variables. The proportion of patients Oivent screening in the United States again appears to vary between individuals, s health. Only 25 home what doctors report regularly Moderately suitable screening for HCC patients, compared to 84 doctors, The members of the association are the Study of Liver Diseases. In a study of 157 patients with HCC at least three U.
S. Veterans Affairs Medical Center, 39 patients with a known risk factor for HCC re U-screening diagnosed. with the exception of Hong Kong, where screening was carried out as part of the study, is the screening of high-risk populations, the standard of care in Asia. Are diagnosed at earlier stages, the East Asian L Direction better able to treatments to use the treatment paradigms to significantly affect populations and clinical studies. Two diagnostic pathology and clinical diagnosis vary